The 14 analysts offering 12-month price forecasts for Blueprint Medicines Corp have a median target of 120.00, with a high estimate of 152.00 and a low estimate of 81.00. The median estimate represents a +25.51% increase from the last price of 95.61.
The current consensus among 15 polled investment analysts is to Buy stock in Blueprint Medicines Corp. This rating has held steady since December, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$1.75
Reporting Date May 12
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.